Karneboge, Jonas
ORCID: 0009-0000-9272-6535, Haberstroh, Julia
ORCID: 0000-0003-3133-011X, Geschke, Katharina
ORCID: 0000-0001-7311-0049, Perry, Julia
ORCID: 0000-0001-8112-0298, Radenbach, Katrin
ORCID: 0009-0005-2409-6582, Jessen, Frank
ORCID: 0000-0003-1067-2102 and Rostamzadeh, Ayda
ORCID: 0000-0001-5189-134X
(2025).
Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.
Alzheimer's & Dementia, 21 (1).
pp. 1-8.
Wiley.
ISSN 1552-5260
|
PDF
Alzheimer s Dementia - 2025 - Karneboge - Facing the new diagnostic and treatment options of Alzheimer s disease The.pdf Bereitstellung unter der CC-Lizenz: Creative Commons Attribution Non-commercial No Derivatives. Download (305kB) |
Abstract
[Artikel-Nr.: e14204] With advances in biomarker‐based detection of Alzheimer's disease (AD) and new treatment options with disease‐modifying treatments (DMTs), we are heading toward a new conceptualization of diagnostics and therapy in the early stages of AD. Yet consensus guidelines on best clinical practices in predictive AD diagnostics are still developing. Currently, there is a knowledge gap regarding counseling and disclosure practices in early symptomatic disease stages, its implications for dementia risk estimation, and DMTs with associated risks and benefits. The crucial feature is the capacity of patients with (mild) cognitive impairment, eligible for DMTs, to consent. This perspective aims to (1) discuss the current challenges in assessing capacity to consent and (2) highlight the importance of a supported (informed) decision‐making process. Measures to facilitate informed decision‐making of patients constitute an ethical approach to enhancing the quality of care in this evolving therapeutic landscape. Highlights: This perspective: Explores biomarker‐based early symptomatic AD detection and the implications for patient care. Emphasizes supported decision‐making in DMTs for MCI and dementia patients. Discusses the need for standardized tools to assess the capacity to consent. Aligns diagnostic and treatment approaches with ethical care standards. Enhances patient autonomy in the evolving AD therapeutic landscape.
| Item Type: | Article |
| Creators: | Creators Email ORCID ORCID Put Code |
| URN: | urn:nbn:de:hbz:38-816385 |
| Identification Number: | 10.1002/alz.14204 |
| Journal or Publication Title: | Alzheimer's & Dementia |
| Volume: | 21 |
| Number: | 1 |
| Page Range: | pp. 1-8 |
| Number of Pages: | 8 |
| Date: | 30 January 2025 |
| Publisher: | Wiley |
| ISSN: | 1552-5260 |
| Language: | English |
| Faculty: | Central Institutions / Interdisciplinary Research Centers Faculty of Medicine |
| Divisions: | CECAD - Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases Faculty of Medicine > Psychiatrie und Psychotherapie > Klinik und Poliklinik für Psychiatrie und Psychotherapie |
| Subjects: | Medical sciences Medicine |
| Uncontrolled Keywords: | Keywords Language anti-amyloid therapy ; biomarkers ; capacity to consent ; communication ; dementia risk estimation ; early diagnosis ; informed consent ; supported decision-making English |
| ['eprint_fieldname_oa_funders' not defined]: | Publikationsfonds UzK |
| Refereed: | Yes |
| URI: | http://kups.ub.uni-koeln.de/id/eprint/81638 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
![]() |
View Item |
https://orcid.org/0009-0000-9272-6535